Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score

American Journal of Hematology
Kristen M SanfilippoBrian F Gage

Abstract

Venous thromboembolism (VTE) is a common cause of morbidity and mortality among patients with multiple myeloma (MM). The International Myeloma Working Group (IMWG) developed guidelines recommending primary thromboprophylaxis, in those identified at high-risk of VTE by the presence of risk factors. The National Comprehensive Cancer Network (NCCN) has adopted these guidelines; however, they lack validation. We sought to develop and validate a risk prediction score for VTE in MM and to evaluate the performance of the current IMWG/NCCN guidelines. Using 4446 patients within the Veterans Administration Central Cancer Registry, we used time-to-event analyses to develop a risk score for VTE in patients with newly diagnosed MM starting chemotherapy. We externally validated the score using the Surveillance, Epidemiology, End Results (SEER)-Medicare database (N = 4256). After identifying independent predictors of VTE, we combined the variables to develop the IMPEDE VTE score (Immunomodulatory agent; Body Mass Index ≥25 kg/m2 ; Pelvic, hip or femur fracture; Erythropoietin stimulating agent; Dexamethasone/Doxorubicin; Asian Ethnicity/Race; VTE history; Tunneled line/central venous catheter; Existing thromboprophylaxis). The score showed s...Continue Reading

References

Feb 24, 2001·Medical Decision Making : an International Journal of the Society for Medical Decision Making·E W SteyerbergJ D Habbema
May 5, 2007·American Journal of Preventive Medicine·Michael PignoneSteven M Weisman
Dec 21, 2007·Leukemia·A PalumboUNKNOWN International Myeloma Working Group
May 6, 2009·Annals of Internal Medicine·Andrew S LeveyUNKNOWN CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)
Feb 2, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antonio PalumboMario Boccadoro
Apr 19, 2012·Haematologica·Sigurdur Y KristinssonOla Landgren
Jul 14, 2012·Blood·Laura RosiñolUNKNOWN Programa para el Estudio y la Terapéutica de las Hemopatías Malignas/Grupo Español de Mieloma (PETHEMA/GEM) group
Jun 1, 2013·Pharmacoepidemiology and Drug Safety·Yingjun ZhouAndrew N Freedman
Nov 14, 2013·Journal of the American Pharmacists Association : JAPhA
Feb 4, 2014·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Maeve P CrowleyOonagh M Gilligan
Jun 17, 2014·Thrombosis Research·Joanna Rupa-MatysekMieczysław Komarnicki
Aug 27, 2014·Circulation·John SimesUNKNOWN INSPIRE Study Investigators (International Collaboration of Aspirin Trials for Recurrent Venous Thromboembolism)
Apr 22, 2015·American Journal of Preventive Medicine·Craig D WilliamsJessina C McGregor
Sep 12, 2015·Journal of the National Comprehensive Cancer Network : JNCCN·Michael B StreiffAnita M Engh
Jan 19, 2016·Journal of Thrombosis and Thrombolysis·John A HeitRichard H White
Apr 14, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Roongruedee ChaiteerakijAnn L Oberg
Aug 2, 2017·Journal of Thrombosis and Haemostasis : JTH·A TosettoG Palareti
Dec 13, 2017·The New England Journal of Medicine·María-Victoria MateosUNKNOWN ALCYONE Trial Investigators
Feb 2, 2018·Circulation·Emelia J BenjaminUNKNOWN American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee
Mar 10, 2018·Blood Cancer Journal·Elias K MaiHartmut Goldschmidt
Jul 14, 2018·Pharmacoepidemiology and Drug Safety·Eric M AmmannStephen S Johnston
Dec 5, 2018·The New England Journal of Medicine·Marc CarrierUNKNOWN AVERT Investigators
Feb 21, 2019·The New England Journal of Medicine·Alok A KhoranaUNKNOWN CASSINI Investigators
Feb 21, 2019·The New England Journal of Medicine·Giancarlo Agnelli
Jul 19, 2019·Journal of the National Comprehensive Cancer Network : JNCCN·Ang LiKristen M Sanfilippo

❮ Previous
Next ❯

Citations

Jan 17, 2020·Cancers·Despina FotiouEvangelos Terpos
Jun 20, 2020·Cancer Control : Journal of the Moffitt Cancer Center·Rachid BazChristine Stone
May 13, 2020·British Journal of Haematology·Tzu-Fei Wang, Aurélien Delluc
Oct 23, 2020·Cancer Investigation·Gary H Lyman, Nicole M Kuderer
Dec 5, 2020·The Oncologist·Alok A KhoranaJeffrey Zwicker
Dec 5, 2020·The Oncologist·Michael B StreiffGregory Piazza
Jan 9, 2021·Journal of Thrombosis and Thrombolysis·Gianfranco LapietraAntonio Chistolini
Nov 3, 2020·Research and Practice in Thrombosis and Haemostasis·Martin W SchoenKristen M Sanfilippo
Jun 10, 2021·British Journal of Haematology·Martha L Louzada
Jul 14, 2021·Postgraduate Medicine·Elliott J BreaJean M Connors
Aug 28, 2021·Journal of Clinical Medicine·Aisling BarrettSiobhán Glavey

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.